Alaya Mikalauskas1, Michael D Parkins2, Keith Poole1. 1. Department of Biomedical and Molecular Sciences, Botterell Hall, Queen's University, Kingston, Ontario, K7L 3N6, Canada. 2. Department of Microbiology, Immunology and Infectious Diseases and Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Abstract
OBJECTIVES: Rifampicin potentiates the activity of aminoglycosides (AGs) versus Pseudomonas aeruginosa by targeting the AmgRS two-component system. In this study we examine the impact of rifampicin on the AG susceptibility of cystic fibrosis (CF) lung isolates of P. aeruginosa and the contribution of AmgRS to AG resistance in these isolates. METHODS: amgR deletion derivatives of clinical isolates were constructed using standard gene replacement technology. Susceptibility to AGs ± rifampicin (at ½ MIC) was assessed using a serial 2-fold dilution assay. RESULTS: Rifampicin showed a variable ability to potentiate AG activity versus the CF isolates, enhancing AG susceptibility between 2- and 128-fold. Most strains showed potentiation for at least two AGs, with only a few strains showing no AG potentiation by rifampicin. Notably, loss of amgR increased AG susceptibility although rifampicin potentiation of AG activity was still observed in the ΔamgR derivatives. CONCLUSIONS: AmgRS contributes to AG resistance in CF isolates of P. aeruginosa and rifampicin shows a variable ability to potentiate AG activity against these, highlighting the complexity of AG resistance in such isolates.
OBJECTIVES: Rifampicin potentiates the activity of aminoglycosides (AGs) versus Pseudomonas aeruginosa by targeting the AmgRS two-component system. In this study we examine the impact of rifampicin on the AG susceptibility of cystic fibrosis (CF) lung isolates of P. aeruginosa and the contribution of AmgRS to AG resistance in these isolates. METHODS: amgR deletion derivatives of clinical isolates were constructed using standard gene replacement technology. Susceptibility to AGs ± rifampicin (at ½ MIC) was assessed using a serial 2-fold dilution assay. RESULTS: Rifampicin showed a variable ability to potentiate AG activity versus the CF isolates, enhancing AG susceptibility between 2- and 128-fold. Most strains showed potentiation for at least two AGs, with only a few strains showing no AG potentiation by rifampicin. Notably, loss of amgR increased AG susceptibility although rifampicin potentiation of AG activity was still observed in the ΔamgR derivatives. CONCLUSIONS: AmgRS contributes to AG resistance in CF isolates of P. aeruginosa and rifampicin shows a variable ability to potentiate AG activity against these, highlighting the complexity of AG resistance in such isolates.
Authors: Lena Raidt; Evgeny A Idelevich; Angelika Dübbers; Peter Küster; Pavel Drevinek; Georg Peters; Barbara C Kahl Journal: Pediatr Infect Dis J Date: 2015-07 Impact factor: 2.129
Authors: David C Young; Jeffery T Zobell; Chris Stockmann; C Dustin Waters; Krow Ampofo; Catherine M T Sherwin; Michael G Spigarelli Journal: Pediatr Pulmonol Date: 2013-09-02
Authors: Calvin Ho-Fung Lau; Sebastien Fraud; Marcus Jones; Scott N Peterson; Keith Poole Journal: Antimicrob Agents Chemother Date: 2013-03-04 Impact factor: 5.191
Authors: Ranjani Somayaji; John C Lam; Michael G Surette; Barbara Waddell; Harvey R Rabin; Christopher D Sibley; Swathi Purighalla; Michael D Parkins Journal: Thorax Date: 2016-09-28 Impact factor: 9.139